TSP-1 reduced C3 and C5 cleavage and formation of the membrane attack complex, attenuating complement-mediated injury in AAV models. Complement activation is a relevant driver in the pathomechanisms ...

Patients who are taking complement inhibitors may still experience breakthrough hemolysis associated with respiratory viral infections. Patients with PNH should be closely monitored for signs of ...

Left untreated, PNH could cause death in about half of patients within 10 years of diagnosis. The primary cause of PNH-related mortality is thromboembolic events. A host of anti-complement strategies, ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, severe, and potentially life-threatening condition. Treatments targeting the complement pathway have revolutionized its management but have ...

Both hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are characterized by thrombotic microangiopathy (TMA), affecting mainly the kidney and brain, respectively. Diagnosis ...

Please provide your email address to receive an email when new articles are posted on . The monoclonal antibody eculizumab has received accelerated approval from the FDA for the treatment of pediatric ...